Girl discusses her options and concerns about third molar / wisdom tooth extraction and postsurgical opioid use with her mother

Connect with Us

If you are a healthcare provider and would like an EXPAREL^® representative to contact you, please fill in the information below and click submit. Or, for immediate assistance, please call 1-855-793-9727.

Required field

Personal Information

First name

Last name

Email address

Professional Information

Credential

Specialty

NPI

Hospital/Practice/Clinic Information

State

ZIP code

Hospital / Practice / Clinic Information

Phone number

So we can best respond to your inquiry, please provide details regarding your question(s).

Click here to opt-in to any future communications from EXPAREL

updates from Pacira

For details on how your personal information may be used, please review our Privacy Notice.

Important Notice

This site is intended to provide medical and product information to healthcare professionals in the United States.

To report an adverse event, email drugsafety@pacira.com or call 1-855-793-9727.

For medical inquiries related to EXPAREL, submit a request to Medical Information or call 1-855-793-9727.

These are not all of the potential important safety considerations for EXPAREL; please see the full Prescribing Information.

Indication

EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia
Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation
If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine
EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients
Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL
EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use
The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression
Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death
Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients
Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use
Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use

Please refer to full Prescribing Information.

See More

Important Safety Information